Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
0.76
-0.04 (-4.51%)
At close: Oct 22, 2026, 4:00 PM EDT
0.76
-0.01 (-0.92%)
Pre-market: Oct 23, 2026, 7:13 AM EDT
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Rα in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Barry David Quart Pharm.D. | CEO & Director |
| Dr. Lei Sun Ph.D. | VP of Biologics & Head of CMC |
| Dr. Srikanth Pendyala M.D. | Senior Vice President of Clinical Development(Consultant) |
| Mr. David L. Szekeres J.D. | President |
| Mr. Jeff Cohn J.D. | General Counsel & Corporate Secretary |
| Mr. Sean T. Ristine | Vice President of Human Resources |
| Ms. Kimberly J. Manhard | Executive VP & Chief Development Officer |
| Ms. Lisa Peraza CPA | Senior Vice President of Finance |
| Date | Type | Document |
|---|---|---|
| 2026-09-30 | 8-K | cntb-20260930.htm |
| 2026-09-15 | 8-K | cntb-20260915.htm |
| 2026-08-12 | 8-K | cntb-20260812.htm |
| 2026-08-12 | 10-Q | cntb-20260630.htm |
| 2026-05-28 | CORRESP | filename1.htm |
| 2026-05-15 | F-3 | d85019df3.htm |
| 2026-05-12 | 8-K | cntb-20260512.htm |
| 2026-05-12 | 10-Q | cntb-20260331.htm |
| 2026-04-23 | 8-K | cntb-20260423.htm |
| 2026-03-31 | 8-K | cntb-20260331.htm |